Join the Non-Hodgkin's Lymphoma group to help and get support from people like you.
Non-Hodgkin's Lymphoma News
Related terms: Cancer, Non-Hodgkin's Lymphoma, Histiocytic Lymphoma, Lymphoblastic Lymphoma, Lymphocytic Lymphoma, Lymphoma, Histiocytic, Lymphoma, Lymphoblastic, Lymphoma, Lymphocytic, Lymphoma, Non-Hodgkin's, Non-Hodgkin Lymphoma
Pesticides Can Equal Smoking in Hiking Risks for Cancer
THURSDAY, July 25, 2024 – Farmers and folks living in agricultural areas may be exposed to levels of pesticides that confer cancer risks that are higher than if they smoked, new research shows....
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
THURSDAY, June 27, 2024 – Immunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among...
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
July 23, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment...
FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan
November 28, 2018 – The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with...
FDA Approves Keytruda (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
KENILWORTH, N.J.--(BUSINESS WIRE) June 13, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Kymriah (tisagenlecleucel) Receives Second FDA Approval to Treat Appropriate Patients with Large B-Cell Lymphoma
Basel, May 1, 2018 - Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the ...
FDA Approves Yescarta (axicabtagene ciloleucel) CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma
October 18, 2017 – The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell...
FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries
ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries....
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of Bendeka (bendamustine hydrochloride) Injection
JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Dec. 8, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and...
FDA Expands Approved Use of Imbruvica (ibrutinib) for Waldenström’s Macroglobulinemia
January 29, 2015 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that be...
FDA Approves Zydelig (idelalisib) for CLL and Lymphoma
July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat...
FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma
July 3, 2014 – The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of...
FDA Approves Imbruvica (ibrutinib) for Mantle Cell Lymphoma
November 13, 2013 – The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. MCL is...
FDA Approves Revlimid (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 5, 2013-- Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for R...